Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001071 · ClinicalTrials.gov registry record · NA

A Study of Stem Cells and Filgrastim

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
24
Enrollment target
2
Study locations

NCT00001071: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00001071 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001071, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional characteristics as well as the viral load in the stem cells obtained following this procedure.

Conditions Studied

HIV Infections

Interventions

  • DRUG Filgrastim

Study Locations (2)

California

  • UCLA CARE Center CRS - Los Angeles

Colorado

  • University of Colorado Hospital CRS - Aurora

Trial Details

FieldValue
Enrollment Target 24 participants
Est. Completion 1998-10
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00001071 record still lists

NCT00001071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Filgrastim is the first listed.

NCT00001071 reports a single indexed study location in California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00001071 about?

NCT00001071 is a clinical study titled "A Study of Stem Cells and Filgrastim". To determine the safety of stem cell harvesting after administration of filgrastim ( G-CSF ) to mobilize bone marrow stem cells into the peripheral blood in patients at various stages of HIV-1 infection as well as in HIV-negative volunteers. To determine the surface phenotypic and functional charact...

What is the current status of trial NCT00001071?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. Estimated completion is 1998-10.

What conditions does trial NCT00001071 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00001071?

The interventions under investigation include: Filgrastim (DRUG).

Who is sponsoring clinical trial NCT00001071?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001071 being conducted?

This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001071's enrollment target sits among peer trials

24 470th of 542 higher than 64 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Related registry views

Source: ClinicalTrials.gov NCT00001071, the US trial registry maintained by the National Library of Medicine. NCT00001071 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.